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Autoantibodies are removed from the repertoire at two checkpoints during B cell develop-
ment in the bone marrow and the periphery. Despite these checkpoints, up to 20% of the 
antibodies expressed by mature naive B cells in healthy humans show low levels of self-
reactivity. To determine whether self-reactive antibodies are also part of the antigen-
experienced memory B cell compartment, we analyzed recombinant antibodies cloned from 
single circulating human IgM+ memory B cells. Cells expressing antibodies specifi  c for 
individual bacterial polysaccharides were expanded in the IgM+ memory compartment. 
In contrast, B cells expressing self-reactive and broadly bacterially reactive antibodies were 
removed from the repertoire in the transition from naive to IgM+ memory B cell. Selection 
against self-reactive antibodies was implemented before the onset of somatic hypermuta-
tion. We conclude that a third checkpoint selects against self-reactivity during IgM+ 
memory B cell development in humans.
The majority of developing human B cells in 
the bone marrow express polyreactive or self-
reactive antibodies, but most of these potentially 
harmful autoantibodies are eliminated from the 
repertoire at two self-tolerance checkpoints 
during early B cell development in the bone 
marrow and the periphery (1, 2). Nevertheless, 
 20% of mature naive B cells in peripheral 
blood of healthy donors express low-affi   nity 
self-reactive antibodies and  5% produce anti-
bodies with low levels of polyreactivity (2).
During immune responses, naive B cells 
undergo affi   nity maturation and selection be-
fore diff  erentiating into either antibody-se-
creting plasma cells or memory B cells (3). In 
humans, circulating memory B cells express ei-
ther IgM or secondary antibody isotypes and are 
  distinguished from naive B cells by cell surface 
CD27 (4–7). IgM+ memory B cells participate 
in T cell–independent (T-I) immune responses 
to polysaccharide antigens and bacterial infec-
tions, whereas class-switched memory B cells 
are produced in germinal centers during T 
cell–dependent (T-D) immune responses (8, 9). 
Furthermore, IgM+, but not class-switched 
memory B cells require a functional spleen 
for their development and maintenance (10). 
Based on their cell surface phenotype and gene 
expression profi  les, it has been proposed that 
IgM+ memory B cells are the circulating form 
of splenic marginal zone (MZ) B cells (11).
Marginal zone B cells were fi  rst identifi  ed 
in the mouse, where (as in humans) they par-
ticipate in T-I immune responses to polysac-
charide antigens and the initial defense against 
blood-borne pathogens (12–14). Experiments 
with Ig transgenic mice show that B cells ex-
pressing transgenic low-affi   nity auto- or poly-
reactive antibodies are selected into the MZ B 
cell compartment (15–20). These broadly re-
active antibodies are believed to be especially 
important in the early phase of adaptive im-
mune responses because of their ability to re-
act with a large number of diff  erent pathogens 
(21, 22). However, the reactivity of antibod-
ies expressed by MZ B cells or IgM+ memory 
B cells has not been studied in normal mice 
or humans.
Here, we describe the reactivity profi  les of 
105 recombinant antibodies cloned from single 
human IgM+ memory B cells isolated from pe-
ripheral blood of three healthy donors. We fi  nd 
that the IgM+ memory B cell compartment is 
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depleted of self-reactive and polyreactive antibodies relative 
to the naive B cell pool.
RESULTS 
Igs expressed by IgM+ memory B cells
To characterize the antibodies produced by IgM+ memory 
B cells, we purifi  ed single cells from peripheral blood of 
three healthy donors and analyzed their antibody heavy and 
light chains. In agreement with previous reports, we found 
that IgM+ memory B cells showed a signifi  cant increase in 
VH3 gene family representation and a decrease in JH6 gene 
usage when compared with mature naive B cells from the 
same donors (Fig. 1, A–C, and references 23–26). As ex-
pected, the decreased JH6 usage was associated with shorter 
CDR3s (Fig. 1, A–C and reference 25). The numbers of 
positively charged residues in IgH CDR3s, as well as Igκ 
and Igλ light chain V and J gene usage, were all compa-
rable in naive and IgM+ memory B cells (Fig. S1, available at 
http://www.jem.org/cgi/content/full/jem.20052033/DC1). 
We conclude that antibodies expressed by IgM+   memory 
diff  er from naive B cells only in VH3 and JH6 usage. 94.7% 
of IgM+ memory antibodies were somatically mutated 
(124/131; Tables S1–S3, available at http://www.jem.org/
cgi/content/full/jem.20052033/DC1) with a mutation fre-
quency of 3.20% for IgVH, 1.62% for IgVκ, and 1.61% for 
IgVλ genes (Fig. 1, D and E). Replacement mutations were 
enriched over silent mutations in CDRs compared with 
framework regions (FWRs) 1–3 (Fig. 1 E). Thus, antibodies 
expressed by IgM+ memory B cells show signs of antigen-
mediated selection.
Self-reactivity profi  les of antibodies from IgM+ 
memory B cells
The self-reactivity profi  les of IgM+ memory and naive B cell 
antibodies from the same donors were compared in ELISAs 
using lysates of the human cell line HEp-2 (Fig. 2 A and ref-
erence 2 for GO and JB). On average, 19.7% of the antibod-
ies from mature naive B cells from three donors JH (17.6%; 
Fig. 2 A), GO (22.8% and reference 2), and JB (16.7% and 
reference 2) were self-reactive (Fig. 2 A and Tables S4–S6, 
available at http://www.jem.org/cgi/content/full/jem.
20052033/DC1). In contrast, only 2.1% of antibodies ex-
pressed by IgM+ memory B cells from the same individuals 
were self-reactive (0% for JH and JB, 4.8% for GO; Fig. 2 A 
and Tables S1–S3). This result was confi  rmed by indirect im-
munofl  uorescence assay (IFA) with HEp-2 cell–coated slides 
(unpublished data). Thus, the frequency of self-reactive anti-
bodies expressed by IgM+ memory B cells was signifi  cantly 
Figure 1.  Ig gene features. (A) IgH V and (B) J gene repertoire and (C) IgH 
CDR3 length of antibodies from mature naive and IgM+ memory B cells. 
(D) The number of mutations and (E) frequency of mutations of VH, Vκ, and Vλ 
genes in antibodies from IgM+ memory B cells as calculatedby the number 
of replacement (R; black bar) and silent (S; white bar) nucleotide exchanges 
per base pair in FWRs and CDRs. The R/S ratio in each region is indicated.JEM VOL. 203, February 20, 2006  395
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lower than that measured in mature naive B cells (Fig. 2 A; 
P < 0.0001 for all donors combined; P = 0.028 for JH, 
P = 0.033 for JB, and P = 0.021 for GO). We conclude 
that B cells expressing self-reactive antibodies are effi   ciently 
excluded from the IgM+ memory B cell pool.
To measure the frequency of polyreactive antibodies in 
mature naive and IgM+ memory B cells, we performed 
ELISAs on ss/dsDNA, LPS, or insulin (Fig. 2 B). As previ-
ously reported, 5.4% (5/93) of the antibodies cloned from 
mature naive B cells from donors GO and JB showed low 
levels of reactivity with at least two of these antigens (2). 
  Antibodies cloned from mature naive B cells of JH were not 
signifi  cantly diff  erent from the previously published result 
showing 8.3% polyreactivity (3/36, P = 0.685; Table S6). 
On average, 6.2% of mature naive B cell antibodies were 
polyreactive (8/129; Fig. 2 B and reference 2). In contrast, 
only 1% of antibodies cloned from IgM+ memory B cells 
were polyreactive (1/105, P = 0.044; Fig. 2 B). In summary, 
polyreactive and self-reactive antibodies comprising 5% and 
20% of the mature naive repertoire, respectively, are rarely 
found in the IgM+ memory antibody pool.
Antibody selection
Our experiments indicate that the transition to the IgM+ 
memory B cell compartment is associated with selection 
against self-reactivity. To determine whether selection oc-
curs before or after somatic hypermutation, we reverted the 
somatic mutations of 27 IgM+ memory B cell antibodies 
to their unmutated germline form and tested the recombi-
nant antibodies for self-reactivity and polyreactivity (Fig. 3, 
Fig. S2, available at http://www.jem.org/cgi/content/full/
jem.20052033/DC1, and Table S7, available at. http://www.
jem.org/cgi/content/full/jem.20052033/DC1). Although an 
average of 19.7% of all antibodies produced by naive B cells 
were self-reactive (Fig. 2 A and reference 2), none of the 27 
reverted antibodies displayed self-reactivity or polyreactivity, 
including the two self-reactive and one polyreactive IgM+ 
memory B cell antibodies (Fig. 3 and Table S7). We con-
clude that naive B cells expressing self-reactive antibodies do 
not contribute to the IgM+ memory B cell compartment. 
Furthermore, the rare IgM+ memory B cells that produce 
antibodies with low levels of self-reactivity acquire this reac-
tivity by somatic hypermutation.
Antibody reactivity with bacteria and bacterial 
polysaccharide antigens 
To determine whether antibodies cloned from IgM+ mem-
ory B cells react with bacteria or T-I bacterial antigens, we 
performed ELISAs using Streptococcus pyogenes, a mixture of 
10 Streptococcus pneumoniae serotypes (1, 3–6, 9V, 14, 18, 19, 
23F); Enterococcus faecalis; Escherichia coli, a protein A mutant 
Figure 2.  Polyreactive and self-reactive antibodies are ex-
cluded from the IgM+ memory B cell compartment. (A) Antibod-
ies from mature naive (donor JH) and IgM+ memory B cells (donors 
JH, GO, JB) were tested for self-reactivity by HEp-2 cell ELISA. HEp-2 
ELISA results for antibodies from mature naive B cells of donors GO 
and JB have been published previously (reference 2). Dotted line 
shows ED38 positive control antibody (references 2, 43). Horizontal 
line shows cut-off OD405 for positive reactivity as determined by com-
parison to low positive control serum (red line) and negative control 
serum (green line) from patients and healthy individuals, respectively. 
Pie charts summarize the frequency of HEp-2 self-reactive and non-
self-reactive clones for all three donors. The number of tested anti-
bodies is indicated in the pie chart center (reference 2). (B) Antibodies 
from mature naive (donor JH) and IgM+ memory B cells (donors JH, 
GO, JB) were tested for polyreactivity by ELISA with ssDNA, dsDNA, 
LPS, and insulin. Dotted lines represent the high positive control anti-
body ED38 (references 2, 43). Horizontal lines show cut-off OD405 for 
positive reactivity as determined by comparison to the previously 
published control antibodies mGO53 (negative control; green line) 
and eiJB40 (low positive control; red line) (reference 2). The frequency 
of   polyreactive antibodies in mature naive B cells from donors GO and 
JB has been published (reference 2). Pie charts show the frequency of 
polyreactive clones in mature naive and IgM+ memory B cell antibodies 
from all three donors with the number of tested antibodies indicated in 
the center (reference 2).396  HUMAN IGM+ MEMORY B CELL ANTIBODIES | Tsuiji et al. 
(SpA-) strain of Staphylococcus aureus (Fig. 4 A); or bacterial 
polysaccharide antigens in human vaccines PNEUMOVAX 
23 (Streptococcus pneumoniae), PedvaxHIB (Haemophilus infl  u-
enzae), and Menomune (Neisseria meningitidis) (Fig. 4 B).
As expected, polyreactive antibodies from mature naive 
(4.3%, 4/91) and IgM+ memory B cells (1%, 1/105) showed 
high levels of reactivity with whole bacteria and bacterial an-
tigens (Fig. 4 and Tables S1–S6). In addition, we found a new 
group of antibodies that showed broad reactivity with bacte-
ria or bacterial polysaccharide antigens, but not with DNA, 
LPS, or insulin (Fig. 4 and Tables S1–S6). These antibodies 
comprised 8.8% (8/91) of the mature naive but only 2.9% 
(3/105) of the IgM+ memory B cell repertoire (Fig. 4 C). 
When combined, the broadly bacterially reactive antibodies 
comprised 13.1% of the mature naive and 3.9% of the IgM+ 
memory B cell compartment; overall, IgM+ memory B cells 
show a lower frequency of broadly bacterially reactive anti-
bodies than mature naive B cells (P = 0.0195).
Among 91 antibodies from naive B cells and 105 anti-
bodies from memory B cells tested, we found only two anti-
bodies with high levels of specifi  c reactivity against bacterial 
antigens. Both antibodies were cloned from IgM+ memory 
B cells from donor JB (2/27, 7.4%) who had previously 
been vaccinated and both recognized polysaccharides from 
the serotype 11A vaccine strain of Streptococcus pneumoniae 
  contained in PNEUMOVAX 23 (Fig. 4 B, top right; Tables 
S1–S3, and Fig. S3, available at http://www.jem.org/cgi/
content/full/jem.20052033/DC1).
VH3 gene usage and SpA reactivity
VH3 genes are overrepresented in IgM+ memory B cells and 
several members of the VH3 gene family bind to modifi  ed 
Staphylococcus protein A (mSpA) in an Fc-independent 
manner (27, 28). This association led to the suggestion that 
SpA binding is positively selected in IgM+ memory B cells 
(29). To determine if SpA binding is involved in selection, we 
compared VH3 antibodies cloned from naive and IgM+ 
  memory B cells for mSpA binding by ELISA (Fig. 5, A and B, and 
Fig. S4, available at http://www.jem.org/cgi/content/full/
jem.20052033/DC1). We found that 70.0% of VH3-positive 
antibodies from mature naive B cells showed mSpA binding. 
In contrast, only 54.3% of VH3-positive antibodies from 
IgM+ memory B cells were SpA reactive (Fig. 5, A and B, 
  Tables S1–S3, and Fig. S4).
To further determine if non–SpA-reactive antibodies 
from IgM+ memory B cells had lost SpA binding as a result 
of somatic mutation, we reverted 27 of these antibodies into 
their unmutated counterparts. After reversal of V gene muta-
tions, 10 out of the 27 reverted antibodies became strongly 
mSpA reactive (Fig. 5 C). Our results suggest that SpA bind-
ing is not a selective advantage because it is frequently lost in 
the transition between the naive and IgM+ memory B cell 
compartments as a result of V gene somatic hypermutation.
D  I  S  C  U  S  S  I  O  N 
Antibody genes in IgM+ memory B cells are somatically mu-
tated, and show signs of antigen-mediated selection with in-
creased numbers of replacement mutations in IgH and IgL 
chain CDRs (5, 11, 23–25, 30–34). However, the develop-
ment of somatically mutated IgM+ memory B cells does not 
require CD40L or CD40 and, therefore, these cells appear to 
be germinal center independent (33). Phenotypically, IgM+ 
memory B cells resemble MZ B cells and are thought to be 
their circulating counterparts (11). In support of this idea, 
IgM+ memory B cells are strongly reduced in splenectomized 
and asplenic patients and cannot be detected in infants, where 
Figure 3.  Self-reactivity and polyreactivity profi  les of mutated 
IgM+ memory B cell antibodies in comparison with their unmutated 
counterparts. IgH and IgL chains from IgM+ memory B cell antibodies 
were reverted into their germline counterparts by PCR. (A) Recombinant 
antibodies were tested for self-reactivity by HEp-2 ELISA. Dotted line 
shows ED38 positive control antibody (references 2, 43). Horizontal line 
shows cut-off OD405 for positive reactivity as determined by comparison 
to low positive control serum (red line) and negative control serum (green 
line) from patients and healthy individuals, respectively. (B) Recombinant 
antibodies were tested for polyreactivity by ELISA with ss/dsDNA, insulin 
and LPS. Dotted lines represent the high positive control antibody ED38 
(references 2, 43). Horizontal lines show cut-off OD405 for positive reactiv-
ity as determined by comparison to the previously published control anti-
bodies mGO53 (negative control; green line) and eiJB40 (low positive 
control; red line) (reference 2).JEM VOL. 203, February 20, 2006  397
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the marginal zone is still populated with mature naive B cells 
(10, 35). In all of these cases and in a sub-group of common 
variable immunodefi  ciency (CVID) patients, loss of circulat-
ing IgM+ memory B cells is associated with a specifi  c increase 
in susceptibility to infection with encapsulated bacteria (10, 
11). Consistent with the idea that circulating IgM+ memory 
B cells play an important role in these infections, we found 
antibodies with high specifi  city for streptococcal polysaccha-
rides enriched in this B cell compartment after immunization 
with PNEUMOVAX 23 (9–11).
In mice, MZ B cell development is promoted by trans-
genic expression of B cell antigen receptors with low levels of 
self-reactivity or polyreactivity (15–20). For example, MZ 
B cells but few follicular B cells develop in transgenic mice 
expressing a polyreactive VH81x heavy chain (15, 16). Mouse 
MZ B cells are optimally anatomically positioned to react 
with blood-borne pathogens and expression of low affi   nity 
broadly reactive antibodies by these cells would be consistent 
with a protective role early in infection (13, 14).
Human IgM+ memory B cells are enriched in VH3 an-
tibodies, some of which bind SpA (23–25, 27, 28). Based on 
sequence information, it was proposed that this might refl  ect 
selection into the IgM+ memory/MZ B cell compartment 
for cells reactive with common blood-borne pathogens (29). 
However, we fi  nd that VH3 antibodies cloned from IgM+ 
memory B cells are not more SpA reactive than VH3 antibod-
ies from mature naive B cells and, in many cases, have lost SpA 
reactivity by somatic mutation. In addition, broadly   bacterially 
reactive antibodies are selected against during IgM+   memory 
B cell development. These observations were surprising 
Figure 4.  Whole bacteria and bacterial polysaccharide ELISAs. 
(A) Non-polyreactive antibodies from mature naive (n = 79) and IgM+ memory 
B cells (n = 101) from three healthy donors were tested for reactivity with 
whole cell bacteria (Staphylococcus aureus, Streptococcus pyogenes, Strep-
tococcus pneumoniae, Enterococcus faecalis, Esherichia coli) or (B) bacterial 
polysaccharide vaccines (PNEUMOVAX 23, PedvaxHIB, Menomune) by ELISA. 
Dotted line shows the positive control antibody ED38 (references 2, 43). 
Horizontal line shows cut-off OD405 for positive reactivity as determined by 
comparison to the negative control antibody mGO53 (green line) and the 
low positive control antibody eiJB40 (red line) (reference 2). (C) Pie charts 
summarize the frequency of polyreactive antibodies that recognize ssDNA, 
dsDNA, LPS, insulin, bacteria and bacterial polysaccharides (black), the fre-
quency of antibodies polyreactive with bacteria and bacterial polysaccha-
rides (gray), and the frequency of non-polyreactive antibodies (white) in 
mature naive and IgM+ memory B cells in all three donors. The number 
of tested antibodies is indicated in the pie chart centers.398  HUMAN IGM+ MEMORY B CELL ANTIBODIES | Tsuiji et al. 
  because they appear to be at odds with the transgenic mouse 
experiments showing that B cells expressing polyreactive anti-
bodies are selected into the MZ B cell compartment (15–20). 
However, the reactivity of marginal zone B cells has never 
been measured in normal mice or humans and experiments 
with anti–hen egg lysozyme (HEL) transgenic mice show that 
the development, half-life, and anatomic distribution of self-
  reactive B cells is altered in the absence of competition (36, 37). 
For example, anti-HEL transgenic B cells develop normally in 
the presence of HEL and fi  ll the follicular B cell compartments; 
however, the same B cells fail to enter the follicular compart-
ment when exposed to HEL in the presence of normal B cells 
(36, 37). Thus, the repertoire of authentic MZ B cells develop-
ing in the presence of a complete B cell repertoire may diff  er 
from those that arise in transgenic mice in the absence of com-
petition. Alternatively, MZ B cell selection might diff  er from 
mouse to human, or the circulating IgM+ memory B cell re-
pertoire could represent a subset of cells entirely diff  erent from 
the phenotypically similar MZ B cells in the human spleen.
Most newly arising antibodies are self-reactive, but many 
of these are removed from the repertoire during B cell devel-
opment in the bone marrow and the periphery (1, 2). Nev-
ertheless, 20% of mature naive B cells in healthy humans 
express antibodies with low levels of self-reactivity (2). De-
spite the prevalence of self-reactive B cells in the naive B cell 
compartment, these potentially autotoxic antibodies are not 
likely to make a signifi  cant contribution to the circulating 
repertoire because naive B cells do not secrete high levels of 
antibodies. In contrast with naive B cells, IgM+ memory B 
cells are readily induced to proliferate in an Ig-independent 
manner and diff  erentiate into antibody-secreting plasmablasts 
(38–41); therefore, any autoantibody producing IgM+ mem-
ory B cells would more likely be autotoxic. Our experiments 
suggest that, under physiologic conditions, this possibility is 
averted by a third checkpoint for B cell tolerance between 
the naive and IgM+ memory compartment imposed before B 
cells undergo somatic hypermutation.
MATERIALS AND METHODS
Single cell sorting. The study was performed in accordance with institu-
tional review board–reviewed protocols of The Rockefeller University and all 
samples were obtained after signed informed consent. Single cell sorting was 
performed as described previously (2, 42). In brief, peripheral blood 
B cells were enriched by incubation with RossetteSep (Stem Cell Technol-
ogy, Inc.) followed by Ficoll-Paque Plus (GE Healthcare) gradient centrifuga-
tion. Enriched B cells were stained with anti–human CD19-allophycocyanin, 
anti–human CD10-PE, anti–human CD27-FITC, and anti–human IgM-
  biotin (BD Biosciences), and biotinylated anti–human IgM antibody was 
  visualized using Streptavidin-PeCy7 (Caltag Laboratories). Single mature 
naive B cells (CD19+CD10−IgM+CD27−) and IgM+ memory B cells 
(CD19+CD10−IgM+CD27+) were isolated by FACS into 96-well plates 
containing 4 μl of 0.5 × PBS, 10 mM DTT, 8 U RNAsin (Promega), and 3 U 
Prime RNase Inhibitor (Eppendorf) using a FACSvantage (Becton Dickinson). 
All samples were immediately frozen on dry ice and stored at −70°C.
Ig gene RT-PCR amplifi   cation and expression vector cloning. 
Antibodies were cloned as described previously (2, 42). In brief, single cell 
cDNA was synthesized in the original sort plates in a total volume of 14.5 μl 
(4 μl sort lysis solution + 10.5 μl RT-PCR reaction mix containing 150 ng 
random hexamer primer [pd{N}6]; GE Healthcare), 0.5% vol/vol Igepal 
CA-630 (NP40; Sigma-Aldrich), 7 mM DTT, 4 U RNAsin (Promega), 7.5 U 
Primer RNase Inhibitor (Eppendorf), 1.2 mM each dNTP, and 50 U Su-
perscript II RT (Invitrogen). cDNA was synthesized at 42°C for 55 min. In-
dividual IgH (μ) and IgL chain (κ or λ) gene rearrangements were amplifi  ed 
in two successive rounds of PCR (50 cycles each) using primers as described 
previously (2, 42). Ig genes were amplifi  ed from 3.5 μl cDNA or fi  rst PCR 
product in 40 μl of total reaction volume with 0.2 μM 5′ and 3′ primers or 
primer mixes, 312.5 μM each dNTP and 1 U Hotstar Taq DNA polymerase 
(QIAGEN). All PCR products were purifi  ed   (Qiaquick; QIAGEN), se-
quenced, and analyzed by Ig BLAST comparison with GenBank. Digested 
PCR products were purifi  ed and cloned into human IgG1, Igκ, or Igλ ex-
pression vectors (2, 42). Plasmids were sequenced to select clones with in-
serts identical to the original PCR product.
Figure 5.  VH3 and modifi  ed SpA reactivity. (A) VH3-positive antibod-
ies from mature naive and IgM+ memory B cells were tested for reactivity 
with mSpA by ELISA. Horizontal line shows cut-off OD405 for positive reac-
tivity as determined by comparison to ED38 (dotted line, VH1-69 and ref-
erences 2, 43), the negative control antibody mGO53 (green line, VH4-39, 
and reference 2) and the low positive control antibody eiJB40 (red line, 
VH3-23 and reference 2). The frequency of mSpA-reactive clones and the 
number of antibodies tested are indicated below the graphs. (B) The fre-
quency of mSpA-reactive antibodies for individual VH3-family members is 
shown for mature naive (black bars) and IgM+ memory (gray bars) B cell 
antibodies with the number of antibodies tested indicated. (C) mSpA-bind-
ing as measured by ELISA for mutated IgM+ memory B cell antibodies 
(n = 22) and their unmutated counterparts after reversion of IgM+ memory 
B cells antibody IgH and IgL chain genes into their germline forms by PCR.JEM VOL. 203, February 20, 2006  399
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Antibody production and purifi  cation. Recombinant antibodies were 
produced as described previously (2, 42). In brief, 293A human embryonic 
kidney cells were cultured in DMEM supplemented with 10% ultra-low 
IgG FCS (Invitrogen) and cotransfected with 12.5 μg of IgH and IgL chain 
encoding plasmid DNA by calcium phosphate precipitation. Cells were 
washed with serum-free DMEM for 8-12 h after transfection and thereafter 
cultured in DMEM supplemented with 1% Nutridoma SP (Roche). Super-
natants were collected after 7 d of culture. For self-reactive HEp-2 ELISAs, 
antibodies were purifi  ed with protein G–Sepharose (GE Healthcare).
Bacteria strains and media. Streptococcus pneumoniae strains DCC1355 
  (serotype 19), DCC1335 (9V), DCC1420 (23F), DCC1490 (14), DCC1714 
(3), DCC1850 (6), AR314 (5), AR620 (1), GB2017 (18), GB2092 (4), and 
Enterococcus faecalis V12 were grown in Brain Heart Infusion broth (Sigma-
Aldrich).  Streptococcus pyogenes D471 was grown in Todd-Hewitt broth 
(Sigma-Aldrich). Staphylococcus aureus protein A-negative Foster strain 8325–4 
spa::Ebr was grown in super broth (10 g/liter MOPS, 30 g/liter tryptone, 20 
g/liter yeast extract). Escherichia coli was grown in Luria-Bertani medium. 
Cell counts from log-phase bacteria cultures were determined before treat-
ment with 50 μg/ml mitomycin-C for 1 h at 37°C. Whole bacteria were 
suspended at a concentration of 108/ml PBS for ELISA.
ELISA. To measure reactivity of antibodies with individual antigens, mi-
crotiter plates (COSTAR 9018) were coated with 50 μl/well of 10 μg/ml 
of ssDNA, dsDNA, LPS (Sigma-Aldrich), or 5 μg/ml of recombinant hu-
man insulin (Sigma-Aldrich) or 10 μg/ml of human bacterial polysaccharide 
vaccines PNEUMOVAX 23 (Merck & Co.), PedvaxHIB (Merck & Co.), or 
Menomune (Aventis) or 10 μg/ml of modifi  ed protein A. To measure anti-
body reactivity with specifi  c bacteria, microtiter plates were coated with 
100 μl/well of 100 μg/ml poly-l-lysine, 25 μl/well of bacteria solution, and 
25 μl/well of 0.2% gluteraldehyde were added at room temperature for 
20 min. Plates were centrifuged at 1,500 g for 20 min and washed with PBS. 
To block aldehydes, 50 μl/well of 0.1 M l- lysine in PBS was added and 
wells were washed with PBS.
Antibody concentrations in supernatants and after purifi  cation  were 
  determined by anti–human IgG1 ELISA using human monoclonal IgG1 as 
standard (Sigma-Aldrich). For polyreactivity and bacterial ELISAs, superna-
tants were adjusted to a starting antibody concentration of 1 μg/ml and with 
three subsequent 1:4 dilutions in PBS. Samples were considered negative if 
the OD405 did not exceed a threshold value at any of the four dilutions in at 
least two independent experiments as indicated in each graph. In all assays, 
threshold values were set using the negative control antibodies mGO53, 
low positive control eiJB40, and high polyreactive antibody ED38 (2, 43). 
HEp-2 cell self-reactivity ELISAs used QUANTA Lite ANA ELISA plates 
(INOVA Diagnostics) and purifi  ed antibodies at a concentration of 10 μg/ml 
with three subsequent 1:4 dilutions in PBS. Positive and negative controls 
for HEp-2 ELISAs included control sera from patients and healthy individ-
uals (INOVA Diagnostics) as well as ED38 and were included in every ex-
periment. Consistent with our previously published results, the negative and 
low positive serum was used to determine the cut-off   OD405 for reactivity in 
each experiment (2). Cut-off   OD405 levels vary among experiments depend-
ing on the absolute OD405 values and antibody  concentrations, but allow us 
to compare the data among individual experiments. Antibodies were consid-
ered reactive if they showed reactivity levels above the cut-off   OD405 in at 
least two independent experiments and if the results could be confi  rmed by 
IFA on HEp-2 cell–coated slides (unpublished data). All ELISAs were devel-
oped with horseradish peroxidase–labeled goat anti–human IgG Fc antibodies 
(Jackson ImmunoResearch Laboratories) and horseradish peroxidase sub-
strates (Bio-Rad Laboratories). OD405 was measured with a microplate reader 
  (Molecular Devices).
Reversion of somatic hypermutations into germline sequences. 
Antibodies for reversion were chosen randomly and are listed in Table S7. 
Mutated IgH and IgL chain genes were reverted to their germline sequence 
by two separate PCR reactions for the V gene and the (D)J gene followed 
by a third overlap PCR to fuse the two PCR products (44). Germline V genes 
were amplifi  ed from previously cloned Ig genes from unmutated naive B cell 
templates using FWR1 sense and FWR3 antisense primers. Germline (D)J 
sequences were generated with sense primers spanning the 3′ end of the V 
gene and the CDR3 region and antisense primers in the J gene. A second 
20-cycle PCR reaction fused the two overlapping V and (D)J PCR frag-
ments to generate unmutated germline antibody sequences (Fig. S2). All 
unmutated IgH and IgL chain PCR products were sequenced before and 
after cloning into the corresponding expression vectors to confi  rm the lack 
of mutations. For all clones’ mutated and unmutated IgH and IgL chain 
CDR3 regions, Ig gene repertoire and reactivity profi  les are summarized 
in Table S7.
Statistics. p-values for Ig gene repertoire analysis, analysis of positive charges 
in IgH CDR3, and antibody reactive were calculated by 2 × 2 of 2 × 5 
Fisher’s Exact test or Chi-square test. p-values for IgH CDR3 length were 
calculated by two-tailed Student’s t test.
Online supplemental material. Fig. S1 shows positive charges in IgH 
CDR3, IgV, and IgJ gene usage for Igκ and Igλ light chains from mature 
naive and IgM+ memory B cell antibodies. Fig. S2 shows the PCR-medi-
ated reversion strategy of mutated IgM+ memory B cell antibodies into their 
unmutated germline forms. Fig. S3 shows specifi  city with serotype 11A 
polysaccharides from Strep. pneumoniae for PNEUMOVAX 23–reactive an-
tibodies from donor JB. Fig. S4 shows ELISA reactivity with mSpA for VH3 
family antibodies from IgM+ memory B cells and their unmutated counter-
parts. Tables S1–S6 show IgH and IgL chain characteristics and antibody re-
activities with ssDNA, dsDNA, LPS, insulin, HEp-2, mSpA, Staph. aureus 
(A-), Strep. pyogenes, Strep. pneumoniae, Ent. faecalis, E. coli, PNEUMOVAX 
23, PedvaxHIB, and Menomune from IgM+ memory B cells and mature 
naive B cells of donors JB, GO, and JH. Table S7 shows IgH and IgL chain 
gene repertoire, reactivity profi  les, and mutated and unmutated CDR3 se-
quence of antibodies selected for reversion. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20052033/DC1.
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